



**Belsomra (suvorexant)
Dayvigo (lemborexant)
Quviviq (daridorexant)
Effective 02/01/2023**

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Belsomra and Dayvigo are orexin receptor antagonists indicated for the following:

- Belsomra (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Dayvigo (lemborexant) is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
- Quviviq (daridorexant) is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with the requested medication excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members when **ALL** the following criteria are met, and documentation is provided:

1. Member has a diagnosis of insomnia characterized by difficulty with sleep onset and/or sleep maintenance
2. The member has a documented inadequate treatment response or intolerance to **TWO** of the following, or a contraindication to **ALL** of the following:
 - a. Eszopiclone
 - b. Ramelteon
 - c. Zaleplon

- d. Zolpidem immediate release or extended release
- 3. **ONE** of the following:
 - a. Requested quantity is \leq one unit/day
 - b. Medical necessity for $>$ one unit/day
- 4. Requests for **Dayvigo**, an inadequate response, adverse reaction, or contraindication to Belsomra
- 5. Requests for **Quviviq**, an inadequate response, adverse reaction, or contraindication to **BOTH** of the following:
 - a. Belsomra
 - b. Dayvigo

Additional criteria may apply for members under the age of 18. Please refer to the Pediatric Behavioral Health Medication Initiative guideline for criteria.

Continuation of Therapy

Reauthorization requires physician documentation of improvement of member’s condition.

Limitations

1. Authorizations will be approved for 24 months.
2. The following quantity limits apply:

Belsomra 5mg, 10mg, and 20mg	30 tablets per 30 days
Dayvigo 5mg and 10mg	30 tablets per 30 days
Quviviq 25mg and 50mg	30 tablets per 30 days

References

1. Belsomra (suvorexant) [prescribing information]. Whitehouse Station, NJ: Merck, Sharpe & Dohme Corp.; July 2018. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. American Academy of Sleep Medicine (AASM). J Clin Sleep Med. 2008; 4:487-504.
2. Wilson SJ, Nutt DJ, Argyropoulos SV, et al. British Association for Psychopharmacology consensus on evidenced-based treatment of insomnia, parasomnias and circadian rhythm disorders. J of Psychopharmacology.2010;1:1-25.
3. Bonnet MH, Arand DL. Treatment of Insomnia. In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate; 2015. Available at: <http://www.uptodate.com/utd/index.do>
4. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An Updated for 2015. An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2015;11(10):1199-1236.
5. Dayvigo [package insert]. Woodcliff Lake, NJ: Eisai; December 2019.
6. Quviviq [package insert]. Radnor, PA: Idorsia Pharmaceuticals; October 2022.

Review History

11/16/2015 – Reviewed
 12/01/2016 – Reviewed & revised
 11/27/2017– Reviewed & revised
 11/26/2018 – Reviewed & revised



01/22/2020 – Added started & stabilized criteria

3/17/2021 – Reviewed at March P&T, added Dayvigo to criteria; updated length of approval to 24 months. Effective 05/01/21.

9/21/2022 – Reviewed and Updated for Sept P&T; Separated out Comm/Exch vs. MH criteria. Dayvigo requires trial of Belsomra. Expanded diagnosis to allow difficulty in sleep onset and/or sleep maintenance Effective 11/1/22

11/16/2022 – Reviewed and updated for Nov P&T. Matched MH UPPL criteria. Added new drug Quviviq (daridorexant) to criteria. Effective 2/1/23.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.